SmartPDT® presented at EADV Spring Symposium 2021

siHealth proud to announce two expert talks on the SmartPDT® solution during the virtual EADV Spring Symposium "A new season for Dermatology and Venereology" (6th-7th May 2021)

siHealth is delighted to announce its presence with two talks about the SmartPDT® telemedicine solution during the European Academy of Dermatology and Venereology (EADV) Spring Symposium “A new season for Dermatology and Venereology”, to be held on 6th-7th May 2021. The event will be fully virtual and CME-CPD accredited for the dermatology & venereology community.

The two talks will be done by world experts in the field, on the topic of SmartPDT® solution for the digital management of daylight Photodynamic Therapy (dPDT). dPDT is a modern, non-invasive, low pain, field-directed treatment of Actinic Keratosis (AK). As the COVID-19 pandemic scenario has emphasised, dermatologists and clinical staff need to find new ways to treat and manage AK patients from remote. dPDT can help, thanks to its high potential for being delivered at home and managed from remote. Indeed, it only requires a monitored sunlight exposure of the patient and a proper support for the self-application of the photosensitiser (prodrug). Exactly what SmartPDT® can now provide.

The two speakers will be Dr Ewan Eadie (NHS Tayside, Dundee, UK) and Prof Yolanda Gilaberte (Miguel Servet Hospital, Zaragoza, Spain), who will:

  • Discuss what the pros and cons of dPDT are, including the current critical issues for dPDT application, particularly in the scenario of patient self-administration at home
  • Present the possible methods for overcoming the obstacles of home-based self-administration of dPDT
  • Introduce the new digital home telemedicine system SmartPDT® for the management of dPDT therapy, in clinical and home-based settings

Daylight PDT critical issues: how can they be managed with SmartPDT®?

Dr Ewan Eadie is the Head of Scientific Services for Photobiology and Optical Radiation at the Ninewells Hospital of Dundee (NHS Tayside, UK).

Dr Eadie will present how the daylight Photodynamic Therapy (dPDT) has a great number of advantages as a treatment for Actinic Keratosis (AK) & field change. One disadvantage is that exposure conditions required can be an issue for patients & practitioners, especially in the self-administration scenario. The methods and recommendations provided by the SmartPDT® solution to overcome these constraints are critically analysed and presented. This will include a particular a focus on SmartPDT’s weather prediction capabilities for planning a suitable dPDT treatment scenario as well as SmartPDT’s accuracy in the remote monitoring of the sunlight dose received by the patient during the treatment. The innovative features presented have the potential to revolutionize how dPDT can be managed and delivered.

SmartPDT®: how to use it in real-life conditions in the clinic

Prof Yolanda Gilaberte is the Head of the Dermatology Service of the University Hospital “Miguel Servet” of Zaragoza (Spain) as well as the VicePresident of the Spanish Academy of Dermatology and Venereology.

Prof Gilaberte will talk about the daylight Photodynamic Therapy (dPDT) as one of the most convenient treatments for Actinic Keratosis (AK). In particular the therapy compliance is high, because it is done in only 1 day, while side effects are very limited. The results are satisfactory for the majority of patients. The dPDT protocol is very well established, however several variables like latitude, season or time of day can influence the amount of solar radiation received and, consequently, the effectiveness of the dPDT as well as its side effects. The SmartPDT® solution allows dermatologists to control the whole dPDT procedure from remote, gaining the maximum therapy effectiveness while minimising the risk of side effects. Prof Gilaberte will also present an observational multi-centre clinical trial carried out in several hospitals in Spain for the use of SmartPDT® for performing dPDT. This will include the patient selection, the protocol and the modalities in which patients and dermatologists are going to use SmartPDT® during the trial.